Abstract:Background: Breast cancer ranks among the most prevalent tumor types worldwide. Copy number amplification of chromosome 8q24 is frequently detected in breast cancer. ZNF623 is a relatively unexplored gene mapped to 8q24. Here, we explore the expression profile, prognostic significance, and biological action of ZNF623 in breast carcinogenesis. Methods: To evaluate the mRNA expression pattern and prognostic relevance of ZNF623 across different cancer types, we conducted bioinformatic analyses. The expression of the gene was suppressed using ZNF623 shRNAs/siRNAs and augmented through transfection with plasmids containing ZNF623 cDNA. Cell viability assay, clonogenic assay, and transwell migration assay were utilized to assess the proliferation, viability, and invasion capacity of breast cancer cell lines. Luciferase reporter assay served as a pivotal tool to ascertain the transcriptional activity of ZNF623. IP-MS and co-IP were employed to validate that ZNF623 interacted with CtBP1. ChIP analysis and ChIP-qPCR were conducted to assess the genes targeted by ZNF623/CtBP1 complex. Flow cytometry was conducted to evaluate the phosphorylation status of p65. Results: ZNF623 expression was notably elevated in breast cancer (BC). Prognostic analysis indicated higher expression of ZNF623 indicated worse survival. Functional experiments discovered that the upregulation of ZNF623 significantly enhanced both the proliferative and migratory capacities of breast cancer cells. Luciferase reporter assay indicated that ZNF623 was a transcription repressor. Immunoprecipitation coupled mass spectrometry analysis revealed a physical association between ZNF623 and CtBP1 in the interaction group. The conjoint analysis of ChIP-seq and TCGA DEG analysis revealed that the ZNF623/CtBP1 complex repressed a series of genes, such as negative regulation of the NF-kappaB signaling pathway. Flow cytometry analysis discovered that knockdown of ZNF623 decreased the phosphorylation level of p65, indicating that ZNF623 could regulate the activity of the NF-κB pathway. Conclusion: ZNF623 predicts poor prognosis of BC and enhances breast cancer growth and metastasis. By recruiting CtBP1, ZNF623 could suppress NF-κB inhibitors, including COMMD1, NFKBIL1, PYCARD, and BRMS1, expression from the transcription level.

Disruption of ZNF334 Promotes Triple-Negative Breast Carcinoma Malignancy Through the SFRP1/ Wnt/β-catenin Signaling Axis

Role of ZNF334 in Cervical Cancer: Implications for EMT Reversal and Tumor Suppression

ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis

ZNF276 promotes the malignant phenotype of breast carcinoma by activating the CYP1B1-mediated Wnt/β-catenin pathway

ZNF326 promotes a malignant phenotype of breast cancer by interacting with DBC1

ZNF623 contributes to breast carcinoma progress by recruiting CtBP1 to regulate NF-κB pathway

Zinc Finger Protein 593 Promotes Breast Cancer Development by Ensuring DNA Damage Repair and Cell Cycle Progression

Zinc-finger Protein 545 Inhibits Cell Proliferation As a Tumor Suppressor Through Inducing Apoptosis and is Disrupted by Promoter Methylation in Breast Cancer.

ZNF133 is a Potent Suppressor in Breast Carcinogenesis Through Dampening L1CAM, a Driver for Tumor Progression

RNA binding protein ZCCHC24 promotes tumorigenicity in triple-negative breast cancer

The Tumor Suppressor Zinc Finger Protein 471 Suppresses Breast Cancer Growth and Metastasis Through Inhibiting AKT and Wnt/β-catenin Signaling

Zinc finger and SCAN domain containing 1, ZSCAN1, is a novel stemness-related tumor suppressor and transcriptional repressor in breast cancer targeting TAZ

ZNF133 is a potent suppressor in breast carcinogenesis through dampening L1CAM, a driver for tumor cell invasion

ZMIZ2 promotes the development of triple-receptor negative breast cancer

Zinc-finger Protein 382 Antagonises CDC25A and ZEB1 Signaling Pathway in Breast Cancer

Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients

ZFHX3 Promotes the Proliferation and Tumor Growth of ER-Positive Breast Cancer Cells Likely by Enhancing Stem-Like Features and MYC and TBX3 Transcription

ZNF331 Represses the Proliferation of Head and Neck Squamous Cell Carcinoma via Co‐Repressor TRIM28

YTHDF3 Facilitates Triple-Negative Breast Cancer Progression and Metastasis by Stabilizing ZEB1 Mrna in an M6a-Dependent Manner

Downregulated ZNF132 predicts unfavorable outcomes in breast Cancer via Hypermethylation modification

Zinc finger protein 468 up-regulation of TFAM contributes to the malignant growth and cisplatin resistance of breast cancer cells